(Q36960048)

17 August 2017

1 reference

title

Carbapenems in the USA: focus on doripenem (English)

1 reference

17 August 2017

main subject

carbapenem antibiotic

0 references

author name string

Philip D Lister

series ordinal

1

1 reference

17 August 2017

publication date

1 October 2007

1 reference

Expert Review of Anti-infective Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

793-809

1 reference

N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal .beta.-lactam antibiotics

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

In vitro antimicrobial activity of doripenem, a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Meropenem: a microbiological overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Properties and potential of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Recent developments in carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Ertapenem: a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Review of the in vitro spectrum of activity of imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

AmpC beta-lactamases: what do we need to know for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Beta-lactamase nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Factors influencing gene expression and resistance for Gram-negative organisms expressing plasmid-encoded ampC genes of Enterobacter origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Genetics of extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Extended-spectrum beta-lactamases: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Carbapenem-resistant Klebsiella pnuemoniae in Singapore producing IMP-1 beta-lactamase and lacking an outer membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to beta-lactams due to reduced expression of the ampC beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Pharmacokinetics of ertapenem in healthy young volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Two decades of imipenem therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Is it safe to use carbapenems in patients with a history of allergy to penicillin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Ertapenem: a review of its use in the treatment of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.5.793

Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.32.1

Identifiers

DOI

10.1586/14787210.5.5.793

1 reference

17 August 2017

1 reference